Agreement expands reach of cell culture labware for researchers and clinicians in the life sciences. WATERTOWN, Mass.)--Captivate Bio, a leading scientific supplier to the life sciences industry, announced today a significant step in its commitment to providing cutting-edge cell culture and labware solutions to its customers. Captivate Bio will enter into a non-exclusive distribution agreement [...]

MENLO PARK, Calif. – Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the first commercial placement of the REM-I platform at Erasmus Medical Center in Rotterdam. This commercial milestone follows placements of pre-commercial instruments laboratories in Europe and the U.S. for Beta testing. In addition, the company announced plans [...]

Offering reduced changeover time while maintaining safety and product quality TOKYO & NEW YORK & DÜSSELDORF, Germany ---Generating cutting-edge therapeutics requires precision, safety, and efficiency from manufacturing equipment. The next generation of oligo manufacturing, the process of producing short sequences of nucleotides (building blocks of DNA or RNA), innovation from Asahi Kasei Bioprocess (AKB), the THESYS™ ACS ERGO [...]

New single cell BCR and TCR profiling products enable immune profiling at unprecedented scale SEATTLE – Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line. The new BCR solution and updates to the existing TCR [...]

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers WILMINGTON, Mass. -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as [...]

QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for [...]

Mark Stevenson, with more than 30 years of experience in the life sciences sector, formerly Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific joins Ultima Genomics’ Board of Directors FREMONT, Calif. --  Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that Mark Stevenson will join its [...]

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples Uppsala, Sweden: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune [...]

KR-HT5 is based on Akoya’s PhenoImager® HT Platform MARLBOROUGH, Mass. and SHANGHAI, China -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as [...]

11 installs successfully completed Novel platform automates and accelerates protein production, enabling scale-up to mg amount in less than 48 hours List of institutes includes, University College London, University of Cambridge, University of Southampton, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute Cambridge, UK: Nuclera, the biotechnology company [...]